Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

1
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
1
ECG Interpretation of Arrhythmias I: Sinus Arrhythmias01:16

ECG Interpretation of Arrhythmias I: Sinus Arrhythmias

189
Arrhythmias are disturbances in the heart's rhythm that lead to abnormal heartbeats. These irregularities can originate from different parts of the heart and are classified based on their origin and nature.
Types of Arrhythmias
Sinus Node Arrhythmias
Sinus Bradycardia: Originating from the sinoatrial (SA) node, sinus bradycardia involves slower impulses, resulting in a heart rate of less than 60 beats per minute (bpm). Causes include sleep, vagal stimulation, beta-blockers, hypothyroidism,...
189
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

382
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
382
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

775
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
775

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing Precision Respiratory Physiology in Critical Care: A 10-Year Survey of the Lung Rescue Team.

Respiratory care·2026
Same author

Critical Care Anesthesiology Milestones 2.0: A Framework for Competency Assessment in Subspecialty Fellowship.

Journal of medical education and curricular development·2026
Same author

Methemoglobin Formation Reflects Systemic Nitric Oxide Uptake: The Critical Role of Delivery Method-Results from Secondary Analysis of a Randomized Controlled Trial.

Journal of cardiothoracic and vascular anesthesia·2026
Same author

Atrial Functional Mitral Regurgitation: Contemporary Mechanisms, Imaging, and Perioperative Implications for Cardiothoracic Anesthesiologists and Intensivists.

Journal of cardiothoracic and vascular anesthesia·2026
Same author

Methemoglobin and Nitrogen Dioxide Levels During Inhaled Nitric Oxide Therapy at 300 Parts per Million in Healthy Volunteers.

Respiratory care·2026
Same author

Inhaled nitric oxide at 300 ppm treats multidrug-resistant <i>Pseudomonas</i> pneumonia in swine and is safe in humans.

Science translational medicine·2026

Related Experiment Video

Updated: Jun 5, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.3K

Analysis of The 2024 ESC/EACTS Guidelines For The Management Of Atrial Fibrillation.

Juan G Ripoll1, Marvin G Chang2, Edward A Bittner2

  • 1Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN.

Journal of Cardiothoracic and Vascular Anesthesia
|December 14, 2024
PubMed
Summary

The 2024 European Society of Cardiology guidelines introduce the AF-CARE pathway for atrial fibrillation (AF) management. This patient-centered approach prioritizes comorbidities, stroke prevention, symptom control, and reassessment for improved outcomes.

Keywords:
ESCarrythmiasatrial fibrillationguidelines

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.5K
Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

19.6K

Related Experiment Videos

Last Updated: Jun 5, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.3K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.5K
Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

19.6K

Area of Science:

  • Cardiology
  • Clinical Guidelines

Background:

  • Atrial fibrillation (AF) management requires a comprehensive, patient-centered strategy.
  • Existing guidelines need updates to reflect current evidence and patient needs.

Purpose of the Study:

  • To present the 2024 European Society of Cardiology (ESC) guidelines for atrial fibrillation (AF).
  • To introduce the AF-CARE pathway: Comorbidity management, Avoiding stroke, Rate/rhythm control, and Evaluation.
  • To emphasize patient-centered care, shared decision-making, and healthcare equity.

Main Methods:

  • Guideline development based on systematic reviews and expert consensus.
  • Risk stratification using CHA₂DS₂-VASc score for anticoagulation decisions.
  • Integration of patient preferences and shared decision-making into management plans.

Main Results:

  • The AF-CARE pathway provides a structured approach to AF management.
  • Direct oral anticoagulants (DOACs) are preferred for stroke prevention.
  • Rhythm control is prioritized, with catheter ablation an option for persistent symptoms.
  • Rate control strategies are essential for symptom management.

Conclusions:

  • The 2024 ESC guidelines offer a holistic, patient-centered framework for AF management.
  • Effective management of comorbidities and stroke risk is crucial.
  • Shared decision-making and healthcare equity are integral to optimizing patient outcomes and quality of life.